Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice

Radiotherapy and Oncology

Volumn 111, Issue 1, 2014, Pages 81-87

  Schütze, Christina ^a,e   Bergmann, Ralf ^b   Brüchner, Kerstin ^a,b   Mosch, Birgit ^b   Yaromina, Ala ^a,f   Zips, Daniel ^c,e   Hessel, Franziska ^a   Krause, Mechthild ^a,e   Thames, Howard ^d   Kotzerke, Jörg ^a,b,e   Steinbach, Jörg ^a,b,e   Baumann, Michael ^a,b,e   Beuthien Baumann, Bettina ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF TEXAS   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Dose escalation; Human tumour xenografts; Hypoxic volume; Local control; Single dose irradiation; Squamous cell carcinoma

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; FLUORINE; MISONIDAZOLE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT;

ARTICLE; BLOOD FLOW; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; LOW DRUG DOSE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION RESPONSE; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RECURRENCE; DRUG DOSE ESCALATION; DRUG EFFECT; FOLLOW UP; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; PET SCANNER; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; DRUG SCREENING; HEAD AND NECK NEOPLASMS; HYPOPHARYNGEAL NEOPLASMS; METABOLISM; NEOPLASM RECURRENCE, LOCAL; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLUORINE RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MICE; MICE, NUDE; MISONIDAZOLE; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902215695     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.02.005     Document Type: Article

References (54)

1. 18F-fluoromisonidazole small-animal PET data in rats J Nucl Med 53 2012 1608 1615
2. M. Baumann, W. Dubois, A. Pu, J. Freeman, and H.D. Suit Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation Int J Radiat Oncol Biol Phys 23 1992 803 810
3. M. Baumann, W. Dubois, and H.D. Suit Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units Radiat Res 123 1990 325 330
4. Baumann M, Krause M. Tumor biology impact on clinical cure rates. In: Molls M, Vaupel P, Nieder C, Ansschereds M. editors. The impact of tumor biology on cancer treatment and multidisciplinary strategies ed. Berlin: Springer; 2009.
5. 18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing Acta Oncol 41 2002 304 312
6. M. Busk, L.S. Mortensen, M. Nordsmark, J. Overgaard, S. Jakobsen, and K.V. Hansen et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice Eur J Nucl Med Mol Imaging 40 2013 186 197
7. R. Butof, A. Dubrovska, and M. Baumann Clinical perspectives of cancer stem cell research in radiation oncology Radiother Oncol 108 2013 388 396
8. W. Choi, S.W. Lee, S.H. Park, J.S. Ryu, S.J. Oh, and K.C. Im et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer Radiother Oncol 97 2010 176 182
9. N. Christian, J.A. Lee, A. Bol, M. De Bast, B. Gallez, and V. Gregoire Immobilization device for in vivo and in vitro multimodality image registration of rodent tumors Radiother Oncol 87 2008 147 151
10. M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, and D.L. Jones et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res 66 2006 9339 9344
11. P. Dirix, V. Vandecaveye, F. De Keyzer, S. Stroobants, R. Hermans, and S. Nuyts Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F- fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI J Nucl Med 50 2009 1020 1027
12. P. Dirix, V. Vandecaveye, F. De Keyzer, S. Stroobants, R. Hermans, and S. Nuyts Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F- fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI J Nucl Med 50 2009 1020 1027
13. 18F- misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 2005 253 260
14. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study BMC Cancer 6 2006 51
15. L.E. Gerweck, S.T. Zaidi, and A. Zietman Multivariate determinants of radiocurability. I: prediction of single fraction tumor control doses Int J Radiat Oncol Biol Phys 29 1994 57 66
16. G.G. Grabenbauer, H. Steininger, M. Meyer, R. Fietkau, T. Brunner, and P. Heinkelmann et al. Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer Radiother Oncol 47 1998 175 183
17. M.W. Gross, U. Karbach, K. Groebe, A.J. Franko, and W. Mueller-Klieser Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids Int J Cancer 61 1995 567 573
18. L. Helbig, A. Yaromina, S.N. Sriramareddy, S. Boke, L. Koi, and H.D. Thames et al. Prognostic value of HIF-1alpha expression during fractionated irradiation Strahlenther Onkol 188 2012 1031 1037
19. R.P. Hill, and L. Milas The proportion of stem cells in murine tumors Int J Radiat Oncol Biol Phys 16 1989 513 518
20. F. Hofheinz, C. Potzsch, L. Oehme, B. Beuthien-Baumann, J. Steinbach, and J. Kotzerke et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets Nuklearmedizin 51 2012 9 16
21. M.R. Horsman, L.S. Mortensen, J.B. Petersen, M. Busk, and J. Overgaard Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 9 2012 674 687
22. A.A. Khalil, S.M. Bentzen, and J. Overgaard Steepness of the dose-response curve as a function of volume in an experimental tumor irradiated under ambient or hypoxic conditions Int J Radiat Oncol Biol Phys 39 1997 797 802
23. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma Ann Nucl Med 25 2011 625 633
24. I.H. Kim, and J.M. Brown Reoxygenation and rehypoxiation in the SCCVII mouse tumor Int J Radiat Oncol Biol Phys 29 1994 493 497
25. M. Krause, C. Schutze, C. Petersen, N. Pimentel, F. Hessel, and A. Harstrick et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC Radiother Oncol 74 2005 109 115
26. M. Krause, A. Yaromina, W. Eicheler, U. Koch, and M. Baumann Cancer stem cells: targets and potential biomarkers for radiotherapy Clin Cancer Res 17 2011 7224 7229
27. T. Kuhnt, A.C. Mueller, T. Pelz, G. Haensgen, M. Bloching, and S. Koesling et al. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy J Cancer Res Clin Oncol 131 2005 758 764
28. H. Lyng, K. Sundfor, and E.K. Rofstad Oxygen tension in human tumours measured with polarographic needle electrodes and its relationship to vascular density, necrosis and hypoxia Radiother Oncol 44 1997 163 169
29. Y. Minagawa, K. Shizukuishi, I. Koike, C. Horiuchi, K. Watanuki, and M. Hata et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study Ann Nucl Med 25 2011 339 345
30. 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode Acta Oncol 49 2010 934 940
31. L.S. Mortensen, J. Johansen, J. Kallehauge, H. Primdahl, M. Busk, and P. Lassen et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
32. J.G. Rajendran, D.L. Schwartz, J. O'Sullivan, L.M. Peterson, P. Ng, and J. Scharnhorst et al. Tumor hypoxia imaging with [f-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 2006 5435 5441
33. J.S. Rasey, Z. Grunbaum, S. Magee, N.J. Nelson, P.L. Olive, and R.E. Durand et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells Radiat Res 111 1987 292 304
34. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 2006 2098 2104
35. V. Rudat, P. Stadler, A. Becker, B. Vanselow, A. Dietz, and M. Wannenmacher et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer Strahlenther Onkol 177 2001 462 468
36. A. Schreiber, M. Krause, D. Zips, A. Dorfler, K. Richter, and S. Vettermann et al. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation Strahlenther Onkol 180 2004 375 382
37. Steel GG. Growth kinetics of tumours: cell population kinetics in relation to the growth and treatment of cancer ed. Oxford: Clarendon Press; 1977.
38. H.D. Suit, and M. Maeda Hyperbaric oxygen and radiobiology of a C3H mouse mammary carcinoma J Natl Cancer Inst 39 1967 639 652
39. D. Thorwarth, S.M. Eschmann, F. Paulsen, and M. Alber Hypoxia dose painting by numbers: a planning study Int J Radiat Oncol Biol Phys 68 2007 291 300
40. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer BMC Cancer 5 2005 152
41. I. Toma-Dasu, J. Uhrdin, L. Antonovic, A. Dasu, S. Nuyts, and P. Dirix et al. Dose prescription and treatment planning based on FMISO-PET hypoxia Acta Oncol 51 2012 222 230
42. Troost EG, Laverman P, Philippens ME, Lok J, van der Kogel AJ, Oyen WJ, et al. Correlation of [(18)F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008; 35:1803-1811 [Erratum. In. Eur J Nucl Med Mol Imaging 2009 1836:1331).
43. Welz S, Thorwarth D, Alber M, Pfannenberg C, Reimold M, Reischl G, et al. Geplante Zwischenanalyse der randomisierten Phase-II-Studie zur Dosiseskalation auf hypoxische Tumorareale bei HNO-Tumoren. Strahlenther Onkol 2013; 189:44.
44. B.G. Wouters, and J.M. Brown Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy Radiat Res 147 1997 541 550
45. M.T. Wyss, M. Honer, P.A. Schubiger, and S.M. Ametamey NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours Eur J Nucl Med Mol Imaging 33 2006 311 318
46. A. Yaromina, A. Eckardt, D. Zips, W. Eicheler, C. Schuetze, and H. Thames et al. Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies Radiother Oncol 92 2009 460 465
47. A. Yaromina, T. Holscher, W. Eicheler, A. Rosner, M. Krause, and F. Hessel et al. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma? Radiother Oncol 76 2005 206 212
48. A. Yaromina, M. Krause, and M. Baumann Individualization of cancer treatment from radiotherapy perspective Mol Oncol 6 2012 211 221
49. A. Yaromina, T. Kroeber, A. Meinzer, S. Boeke, H. Thames, and M. Baumann et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts Int J Radiat Oncol Biol Phys 80 2011 1205 1213
50. A. Yaromina, H. Thames, X. Zhou, S. Hering, W. Eicheler, and A. Dorfler et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation Radiother Oncol 96 2010 116 122
51. A. Yaromina, D. Zips, H.D. Thames, W. Eicheler, M. Krause, and A. Rosner et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies Radiother Oncol 81 2006 122 129
52. K. Zaleska, K. Bruechner, M. Baumann, D. Zips, and A. Yaromina Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts Radiother Oncol 101 2011 80 85
53. D. Zips, S. Boke, T. Kroeber, A. Meinzer, K. Bruchner, and H.D. Thames et al. Prognostic value of radiobiological hypoxia during fractionated irradiation for local tumor control Strahlenther Onkol 187 2011 306 310
54. D. Zips, K. Zophel, N. Abolmaali, R. Perrin, A. Abramyuk, and R. Haase et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer Radiother Oncol 105 2012 21 28